ImetelChat

Hi Irish, I can understand your desire to wait for the Imbark data especially if it comes at the European meetings in June, but what if (as implied by Dr. Scarlett) that doesn't happen until ASH in December. I am concerned given what you have said, that that could be a very long time to be off drug....

Irish, I thought a new topic would be of value. I have already submitted my questions to Scarlett et al (they recommend one question but I submitted three), then Fish added a good one which I hope he submits. If you haven't yet submitted, would you be willing (or someone other shareholder) to ask so...

Irish, sorry to hear John is backsliding. Your observations are very important because a serious gap exists for the current patient population with MF similar to John. If the Mayo trial is no longer enrolling (and will end soon), and the J and J trial has not enrolled since September surely someone ...

Below is an excerpt of a letter I wrote to Anna/John for consideration at the annual shareholders meeting: 1. Please be more specific about the diseases of myelogenous origin being investigated for potential Imetelstat therapy (besides ET, AML, MF and MDS, CML and CLL) either alone or in combination...

Fish, yes, "industry" at these meetings means not only pharma but also financial. bp

To keep it in perspective I would guess about one half are docs, the rest nurses, students, industry, journalists etc. bp

EOM

EHA 10,000
ASCO 30,000
ASH 20,000

Indeed. bp

Agreed on all counts. bp

For my poker playing friends and those students of the tell (Hunt or maybe it was Sargasso this means you). Anyone count the number of times Dr. Scarlett cleared his throat during the last presentation? I did--not many. On a serious note the last update was spectacular. MF R/R continues unchanged an...

Irish, best wishes for continued good health to you both. Please stay in touch. bp

Irish, is John actually leaving the pilot study? I know it was scheduled to close in May. I certainly hope some provision has been made for these patients and they will be offered continued therapy. Can you please clarify what happens? Scarlett said no new patients will be enrolled in the R/R study ...

Irish, sincerest congratulations to you and John and thank you for continuing to share the details of your journey. You have been a voice of great reassurance for those of us "believers" who have gathered bread crumbs and traveled a long road. I hope you have not felt alone as we have gathered infor...

Hunt, re April update, please see previous posts regarding timing of anticipated study update in April. This is not a surprise. But the following: "Geron Corporation (GERN) will host a conference call on April 10, 2017, at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2...

Clinical trials site for MDS study has been updated. Looks like that study will start to reenroll. Watching for MF CT site update for some guidance. bp

This is the last line in the conclusion section of the AACR poster: Prolonged survival was achieved in vivo when combining imetelstat with ABT-199; four mice remained alive ~80 days post end of treatment suggesting a potential cure in these animals The mouse portion of this study apparently looked a...

Geron press release and full poster presentation available on Geron home page. bp

jingle, agree that ASCO this year seems a likely forum for release of data but not for announcements re resumption of study enrollment (or adjustments to protocol e.g. for R/R MF study.) Once the Q2 review is complete I think some announces occur regarding the direction of the current studies and we...

It seems reasonable to expect a PR at the conclusion of AACR (ends tomorrow) probably from Janssen summarizing all of the Janssen presentations including the Imetelstat/Venetoclax combination poster. It would be hard to allow the impressive results from this preclinical study to be left unacknowledg...